

Alessio Amatu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9575092/publications.pdf>

Version: 2024-02-01

73
papers

6,703
citations

136950

32
h-index

79698

73
g-index

76
all docs

76
docs citations

76
times ranked

9780
citing authors

#	ARTICLE	IF	CITATIONS
1	The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 104, 102351.	7.7	34
2	Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment. <i>European Journal of Cancer</i> , 2022, 163, 16-25.	2.8	17
3	Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. <i>Cancers</i> , 2022, 14, 1197.	3.7	9
4	Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients. <i>European Journal of Cancer</i> , 2022, 167, 175-176.	2.8	1
5	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. <i>Cancer Discovery</i> , 2022, 12, 1656-1675.	9.4	48
6	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. <i>Supportive Care in Cancer</i> , 2021, 29, 3971-3980.	2.2	4
7	The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 137.	3.7	46
8	Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. <i>Targeted Oncology</i> , 2021, 16, 309-324.	3.6	14
9	Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression. <i>Nature Immunology</i> , 2021, 22, 735-745.	14.5	36
10	Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis. <i>Cancers</i> , 2021, 13, 2265.	3.7	14
11	Strategies to tackle RAS-mutated metastatic colorectal cancer. <i>ESMO Open</i> , 2021, 6, 100156.	4.5	38
12	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. <i>JCO Precision Oncology</i> , 2021, 5, 1192-1199.	3.0	5
13	446P Bayesian monitoring of lapatinib (L) plus trastuzumab (T) treatment of HER2 positive metastatic colorectal cancer (mCRC): An observational cohort study. <i>Annals of Oncology</i> , 2021, 32, S557.	1.2	2
14	Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. <i>ESMO Open</i> , 2021, 6, 100246.	4.5	11
15	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. <i>Clinical Cancer Research</i> , 2020, 26, 1372-1384.	7.0	66
16	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020, 5, e000911.	4.5	94
17	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. <i>Cancer Treatment Reviews</i> , 2020, 91, 102112.	7.7	29
18	507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer. <i>Annals of Oncology</i> , 2020, 31, S455.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 256-262.e2.	2.3	56
20	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , 2019, 9, 622.	2.8	22
21	Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study. <i>Annals of Oncology</i> , 2019, 30, iv115.	1.2	1
22	Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectal cancer Enhanced) Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 101-110.	10.8	107
23	Adaptive mutability of colorectal cancers in response to targeted therapies. <i>Science</i> , 2019, 366, 1473-1480.	12.6	290
24	Liquid biopsy for rectal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2019, 79, 101893.	7.7	28
25	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1395-1402.	3.7	95
26	Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. <i>Annals of Oncology</i> , 2019, 30, viii5-viii15.	1.2	149
27	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. <i>Cancer Treatment Reviews</i> , 2019, 73, 41-53.	7.7	69
28	Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2276-2284.	7.0	45
29	TRKA expression and NTRK1 gene copy number across solid tumours. <i>Journal of Clinical Pathology</i> , 2018, 71, 926-931.	2.0	12
30	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018, 34, 148-162.e7.	16.8	129
31	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. <i>Gut</i> , 2018, 67, 1995-2005.	12.1	188
32	Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2017, 16, e153-e163.	2.3	110
33	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	9.4	647
34	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	183
35	Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. <i>Annals of Oncology</i> , 2017, 28, 1302-1308.	1.2	32
36	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , 2017, 71, 43-50.	2.8	27

#	ARTICLE	IF	CITATIONS
37	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. Targeted Oncology, 2017, 12, 525-533.	3.6	15
38	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). Cancer, 2016, 122, 574-581.	4.1	121
39	NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open, 2016, 1, e000023.	4.5	444
40	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) Tj ETQq0 0 0 4 BT / Over 10 T	4.5	10
41	Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. ESMO Open, 2016, 1, e000079.	4.5	3
42	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 738-746.	10.7	778
43	Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast. Journal of Clinical Oncology, 2016, 34, e54-e56.	1.6	10
44	Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. Clinical Colorectal Cancer, 2016, 15, 213-221.	2.3	31
45	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1062-1067.	1.2	35
46	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	111
47	Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies. Supportive Care in Cancer, 2016, 24, 1649-1654.	2.2	23
48	HER2 amplification as a molecular bait™ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. Journal of Clinical Oncology, 2016, 34, TPS774-TPS774.	1.6	18
49	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015, 21, 795-801.	30.7	809
50	PD-006 Gemcitabine and Oxaliplatin (GEMOX) with or without Panitumumab as First-Line Treatment in Advanced Biliary Tract Cancer; final results and subgroup analysis of the Vecti-BIL Study. Annals of Oncology, 2015, 26, iv102.	1.2	0
51	Multicenter randomized study of Gemcitabine and Oxaliplatin (GEMOX) +/- Panitumumab as First Line Treatment in K-Ras Wild type Advanced Biliary Tract Cancer; the VECTI-BIL study. Annals of Oncology, 2015, 26, vi90.	1.2	0
52	Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. British Journal of Cancer, 2015, 113, 1730-1734.	6.4	65
53	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Annals of Oncology, 2015, 26, 2092-2097.	1.2	137
54	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Annals of Oncology, 2015, 26, 1994-1999.	1.2	105

#	ARTICLE	IF	CITATIONS
55	Abstract CT110: Randomized phase II study of duligotuzumab + FOLFIRI versus cetuximab + FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). <i>Cancer Research</i> , 2015, 75, CT110-CT110.	0.9	10
56	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3508-3508.	1.6	27
57	Regorafenib in metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 255-265.	2.4	20
58	Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. <i>Science Translational Medicine</i> , 2014, 6, 224ra26.	12.4	228
59	Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. <i>Cancer Discovery</i> , 2013, 3, 658-673.	9.4	585
60	Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 2265-2272.	7.0	96
61	Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?. <i>Annals of Translational Medicine</i> , 2013, 1, 12.	1.7	4
62	Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation?. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 272-276.	0.5	1
63	Intravenous or Oral Vinorelbine Plus Capecitabine As First-Line Treatment in HER2 ⁺ Metastatic Breast Cancer: Joint Analysis of 2 Consecutive Prospective Phase II Trials. <i>Clinical Breast Cancer</i> , 2012, 12, 30-39.	2.4	9
64	Acute Thrombocytopenia: An Unusual Complication Occurring After Drug-Eluting Microspheres Transcatheter Hepatic Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 190-194.	2.0	2
65	Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, S1-S5.	7.7	37
66	Treatment of Chronic Hepatitis C in a Patient Affected by Systemic Sclerosis. <i>Gastroenterology Research and Practice</i> , 2009, 2009, 1-5.	1.5	3
67	Validation of an LC ⁻ MS/MS method for the determination of epirubicin in human serum of patients undergoing Drug Eluting Microsphere-Transarterial Chemoembolization (DEM-TACE). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3543-3548.	2.3	25
68	OEM-TACE: A New Therapeutic Approach in Unresectable Intrahepatic Cholangiocarcinoma. <i>CardioVascular and Interventional Radiology</i> , 2009, 32, 1187-1192.	2.0	66
69	Unusual Complication of Percutaneous Radiofrequency Thermal Ablation of Hepatic Tumor: The Split Electrode. <i>Journal of Vascular and Interventional Radiology</i> , 2008, 19, 625-626.	0.5	0
70	Malignant mesothelioma of the tunica vaginalis testis in a petrochemical worker exposed to asbestos. <i>Anticancer Research</i> , 2008, 28, 1365-8.	1.1	6
71	Oxaliplatin-eluting microspheres for the treatment of intrahepatic cholangiocarcinoma: a case report. <i>Anticancer Research</i> , 2008, 28, 2987-90.	1.1	6
72	Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. <i>Anticancer Research</i> , 2008, 28, 3835-42.	1.1	36

#	ARTICLE	IF	CITATIONS
73	Complications of percutaneous radiofrequency thermal ablation of primary and secondary lesions of the liver. <i>Anticancer Research</i> , 2007, 27, 2911-6.	1.1	24